Choosing the right cell line for renal cell cancer research

Abstract

Cell lines are still a tool of choice for many fields of biomedical research, including oncology. Although cancer is a very complex disease, many discoveries have been made using monocultures of established cell lines. Therefore, the proper use of in vitro models is crucial to enhance our understanding of cancer. Therapeutics against renal cell cancer (RCC) are also screened with the use of cell lines. Multiple RCC in vitro cultures are available, allowing in vivo heterogeneity in the laboratory, but at the same time, these can be a source of errors. In this review, we tried to sum up the data on the RCC cell lines used currently. An increasing amount of data on RCC shed new light on the molecular background of the disease; however, it revealed how much still needs to be done. As new types of RCC are being distinguished, novel cell lines and the re-exploration of old ones seems to be indispensable to create effective in vitro tools for drug screening and more.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-016-0565-8) contains supplementary material, which is available to authorized users.

Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy

“…Taken together, the morphology, immunostaining pattern, and molecular analyses show that CAKI-2 can serve as a representative model for PRCC2. This is consistent with Brodaczewska et al recent review on RCC cell lines describing multiple evidence linking CAKI-2 to PRCC (Brodaczewska et al, 2016). Additionally, CAKI-2 harbors chromosome 8 aberrations, which has also been described in PRCC2 (Furge et al, 2007;Saleeb et al, 2017).…”

“…This is consistent with Brodaczewska et al . recent review on RCC cell lines describing multiple evidence linking CAKI‐2 to PRCC (Brodaczewska et al ., ). Additionally, CAKI‐2 harbors chromosome 8 aberrations, which has also been described in PRCC2 (Furge et al ., ; Saleeb et al ., ).…”

“…Our analysis highlighted the CAKI‐2 cell line as best match for PRCC2 regarding the expression of the top expressed genes as well as the expression of the ARE pathway genes. We confirmed these results by analyzing the in vivo CAKI‐2 cell morphology and immunoprofile which matched those of PRCC2 that was also consistent with literature (Brodaczewska et al ., ). CAKI‐2 is not known to harbor VHL mutations or 3P deletions distinguishing it from CCRCC.…”

“…CAKI-2 is not known to harbor VHL mutations or 3P deletions distinguishing it from CCRCC. Brodaczewska et al described multiple evidence linking CAKI-2 to PRCC (Brodaczewska et al, 2016). Additionally, CAKI-2 has been known to harbor chromosome 8 aberrations, also described in PRCC2 (Furge et al, 2007;Saleeb et al, 2017).…”

ARID1A knockdown triggers epithelial‐mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma

“…To further demonstrate the pathologic relevance of ARID1A deregulation in RCC, all the aforementioned experiments were also performed in the malignant 786-O RCC cell line, which has many characteristics of clear cell RCC with defective expression of von Hippel-Lindau gene (61). Interestingly, the basal levels of ARID1A mRNA and ARID1A protein in the malignant 786-O RCC cells ( Fig.…”